Details of the Drug
General Information of Drug (ID: DMQMR3P)
Drug Name |
DECYL(DIMETHYL)PHOSPHINE OXIDE
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Dimethyldecylphosphine oxide; APO-10; Decyl(Dimethyl)phosphine Oxide; Decyldimethylphosphine oxide; 2190-95-6; 1-(dimethylphosphoryl)decane; decyl(dimethyl)phosphane oxide; Phosphine oxide, decyldimethyl-; decyldimethylphosphino-1-one; DCX; AC1MRFCU; 1-dimethylphosphoryldecane; Dimethyldecyl phosphine oxide; Phosphine oxide,decyldimethyl-; SCHEMBL158223; CTK4E7952; DTXSID90176309; MolPort-000-474-112; ZINC3130911; STK954185; SBB039895; MFCD00226006; AKOS000271378; MCULE-7993897252; DB07641; ST50109137; Dimethyldecylphosphine oxide,
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 218.32 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.9 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 9 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||